RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43^rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast.

Mr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx’s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data demonstrates a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. The data, presented at the recent 2023 ESMO World Congress on Gastrointestinal Cancer, drove the decision from the TIGeR-PaC Data Monitoring Committee (DMC) to continue this pivotal trial.

43rd Annual Canaccord Genuity Growth Conference

Date: August 10, 2023

Time: 10:30 – 10:55 AM ET

Speaker: Shaun Bagai, CEO of RenovoRx

Location: Boston, Massachusetts

Webcast: https://wsw.com/webcast/canaccord89/rnxt/2519572

To schedule a one-on-one investor meeting with RenovoRx’s management team, please contact a conference representative or KCSA Strategic Communications at [email protected].

A webcast of the event will be available for a limited time in the Investors section of the Company’s website.

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a target tissue, while minimizing a therapy’s systemic toxicities. RenovoRx’s unique approach to drug-delivery offers the potential for increased treatment safety, tolerance, and wider therapeutic windows. The Company’s lead product candidate, RenovoGem™ combines gemcitabine with the company’s patented delivery system and is regulated by FDA under the IND 21 CFR 312 pathway. RenovoGem is currently in a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced pancreatic cancer, where interim analysis has demonstrated a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn and Twitter.

Contacts

Investor Contact:
KCSA Strategic Communications

Valter Pinto or Jack Perkins

T:212-896-1254

[email protected]

Media Contact:
KKH Advisors

Kimberly Ha

T: 917 291-5744

[email protected]